US Patent

US7910131 — Method of treating seizures using modified release formulations of oxcarbazepine

Method of Use · Assigned to Supernus Pharmaceuticals Inc · Expires 2027-04-13 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating seizures using controlled-release formulations of oxcarbazepine that provide tailored release profiles.

USPTO Abstract

Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.

Drugs covered by this patent

oxcarbazepine (OXCARBAZEPINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2041`	—	oxcarbazepine
`U-2041`	—	oxcarbazepine
`U-2041`	—	oxcarbazepine

Patent Metadata

Patent number: US7910131
Jurisdiction: US
Classification: Method of Use
Expires: 2027-04-13
Drug substance claim: No
Drug product claim: No
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.